Small molecule inhibitors of PSD95–nNOS protein–protein interactions suppress formalin-evoked Fos protein expression and nociceptive behavior in rats

This publication has 53 references indexed in Scilit:

• Small molecule inhibitors of PSD95-nNOS protein–protein interactions as novel analgesics
  Neuropharmacology, 2015
• The Maintenance of Cisplatin- and Paclitaxel-Induced Mechanical and Cold Allodynia is Suppressed by Cannabinoid CB₂ Receptor Activation and Independent of CXCR4 Signaling in Models of Chemotherapy-Induced Peripheral Neuropathy
  Molecular Pain, 2012
• TargetingN-methyl-D-aspartate receptors for treatment of neuropathic pain
  Expert Review of Clinical Pharmacology, 2011
• Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95
  Nature Medicine, 2010
• Nitric oxide and pain: ‘Something old, something new’
  Acta Anaesthesiologica Scandinavica, 2009
• Selective Activation of Cannabinoid CB2 Receptors Suppresses Neuropathic Nociception Induced by Treatment with the Chemotherapeutic Agent Paclitaxel in Rats
  The Journal of Pharmacology and Experimental Therapeutics, 2008
• Selective activation of cannabinoid CB2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation
  Neuroscience, 2003
• Specific Coupling of NMDA Receptor Activation to Nitric Oxide Neurotoxicity by PSD-95 Protein
  Science, 1999
• Suppression of noxious stimulus-evoked expression of fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist
  Neuroscience, 1996
• Systemic morphine suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in the rat spinal cord
  Journal of Neuroscience, 1990